{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:10:07Z","timestamp":1790208607794,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170832"],"award-info":[{"award-number":["82170832"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jdiacomp.2023.108631","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T12:02:20Z","timestamp":1697544140000},"page":"108631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors"],"prefix":"10.1016","volume":"38","author":[{"given":"Chengye","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108631_bb0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0010","doi-asserted-by":"crossref","first-page":"1055087","DOI":"10.3389\/fimmu.2022.1055087","article-title":"The role of inflammation in immune system of diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications","volume":"13","author":"Yue","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0015","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/582060","article-title":"Diabetic retinopathy: vascular and inflammatory disease","volume":"2015","author":"Semeraro","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00417-020-04884-5","article-title":"A potential novel therapeutic target in diabetic retinopathy: a chemokine receptor (CCR2\/CCR5) inhibitor reduces retinal vascular leakage in an animal model","volume":"259","author":"Monickaraj","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0025","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/IJN.S294807","article-title":"Progress of nanotechnology in diabetic retinopathy treatment","volume":"16","author":"Liu","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154937","article-title":"SGLT-2 inhibitors as cardio-renal protective agents","volume":"127","author":"Caruso","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0035","doi-asserted-by":"crossref","DOI":"10.7326\/J23-0002","article-title":"SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes","volume":"176","author":"Patel","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","article-title":"In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans","volume":"38","author":"Obermeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","article-title":"A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation","volume":"16","author":"Ott","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119018","article-title":"Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; inflammation, angiogenesis and apoptosis","volume":"280","author":"Elkazzaz","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0065","doi-asserted-by":"crossref","first-page":"6342594","DOI":"10.1155\/2022\/6342594","article-title":"Administration of melatonin in diabetic retinopathy is effective and improves the efficacy of mesenchymal stem cell treatment","volume":"2022","author":"Abdel-Kawi","year":"2022","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116101","article-title":"Continuous subcutaneous insulin infusion ameliorates bone structures and mechanical properties in type 2 diabetic rats by regulating bone remodeling","volume":"153","author":"Shi","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0075","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1002\/jcp.30316","article-title":"Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK\/mTOR signaling pathway in obese rats","volume":"236","author":"Jaikumkao","year":"2021","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0080","doi-asserted-by":"crossref","first-page":"1946104","DOI":"10.1155\/2022\/1946104","article-title":"Sequential and dynamic variations of IL-6, CD18, ICAM, TNF-alpha, and microstructure in the early stage of diabetic retinopathy","volume":"2022","author":"Xiao","year":"2022","journal-title":"Dis Markers"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0085","doi-asserted-by":"crossref","first-page":"1052794","DOI":"10.3389\/fendo.2022.1052794","article-title":"Application of urine C-peptide creatinine ratio in type 2 diabetic patients with different levels of renal function","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102460","article-title":"Capsaicin ameliorates diabetic retinopathy by inhibiting poldip2-induced oxidative stress","volume":"56","author":"Liu","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10456-021-09797-3","article-title":"Endothelial cell plasticity at the single-cell level","volume":"24","author":"Pasut","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0105","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0110","first-page":"1460","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a Meta-analysis of individual participant data from randomized","volume":"May 10;145","author":"Neuen","year":"2022","journal-title":"Controlled Trials Circulation"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","article-title":"Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes","volume":"9","author":"Packer","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0120","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.7150\/thno.75121","article-title":"SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia\/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12261","article-title":"Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","volume":"16","author":"Dziuba","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0130","doi-asserted-by":"crossref","first-page":"8867875","DOI":"10.1155\/2020\/8867875","article-title":"The role of SGLT2 inhibitor on the treatment of diabetic retinopathy","volume":"2020","author":"Sha","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0135","article-title":"Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/parkin-mediated mitophagy in diabetic retinopathy","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108300","article-title":"Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by modulating miR-342-3p targeting of CASP1 in diabetic retinopathy","volume":"202","author":"Yu","year":"2021","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603689","article-title":"H3 Relaxin alleviates migration, apoptosis and Pyroptosis through P2X7R-mediated nucleotide binding oligomerization domain-like receptor protein 3 Inflammasome activation in retinopathy induced by hyperglycemia","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13336","article-title":"Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: a meta-analysis","volume":"22","author":"Wong","year":"2021","journal-title":"Obes Rev"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0155","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and Antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor Axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0160","doi-asserted-by":"crossref","first-page":"26428","DOI":"10.1038\/srep26428","article-title":"Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice","volume":"6","author":"Gallo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0165","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0170","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/09273948.2020.1811350","article-title":"Dysregulation of the NLRP3 Inflammasome in diabetic retinopathy and potential therapeutic targets","volume":"30","author":"Raman","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0175","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.2147\/DMSO.S264215","article-title":"NLRP3 blockade suppresses pro-inflammatory and pro-angiogenic cytokine secretion in diabetic retinopathy","volume":"13","author":"Chai","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","article-title":"Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3\/ASC Inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes","volume":"32","author":"Birnbaum","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0190","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.it.2022.07.004","article-title":"NF-kappaB: blending metabolism, immunity, and inflammation","volume":"43","author":"Capece","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0195","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.2174\/1381612826666200730221035","article-title":"Plant compounds for the treatment of diabetes, a metabolic disorder: NF-\u03baB as a therapeutic target","volume":"26","author":"Sahukari","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lfs.2016.06.002","article-title":"Cepharanthine and Piperine ameliorate diabetic nephropathy in rats: role of NF-kappaB and NLRP3 inflammasome","volume":"157","author":"Samra","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0205","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00125-013-3115-6","article-title":"Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-kappaB\/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis","volume":"57","author":"Yang","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s00125-001-0766-5","article-title":"The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm","volume":"Jun;45","author":"Dandona","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0215","article-title":"Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1\/2\/cPLA2\/AA\/ROS pathway independent of hypoglycemic","volume":"13","author":"Hu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0220","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/14656566.2017.1317748","article-title":"The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial","volume":"18","author":"Kato","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0225","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/dom.12889","article-title":"Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes","volume":"19","author":"Nystrom","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108631_bb0230","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc10-0013","article-title":"Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes","volume":"33","author":"Wright","year":"2010","journal-title":"Diabetes Care"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723002295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723002295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:17:59Z","timestamp":1761005879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723002295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1056872723002295"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108631","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023","name":"copyright","label":"Copyright"}],"article-number":"108631"}}